ƽÌØÎå²»ÖÐ

Projects & Partnerships

Ìý

Ìý


Tuberculosis Trials Consortium Clinical Research Services (TBTC)Ìý

Click here for project description


Ìý

Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB

Click here for project description


Ìý

GeneXpert or chest x-rays or tuberculin testing for household contact assessment – a cluster randomized trial

Click here for project description


Ìý

Cost-effectiveness of TB screening in Nunavik

Ìý

Decision tree and supporting materials
Nunavik TB screening manuscript
Nunavik TB screening supplement

Ìý

Enhancing the public health impact of latent TB infection diagnosis and treatment: A pragmatic cluster randomized trial.

ClickÌýhereÌýto access the protocol

ClickÌýhereÌýfor training material

ClickÌýhereÌýfor registry analysis tool

ClickÌýhereÌýfor mTST material

ClickÌýhereÌýfor publications

Click here for questionnaires

Ìý


Ìý

A randomized clinical trial of 4 months Rifampin vs. 9 months Isoniazid for latent TB infection (Phase 3 effectiveness)

&

A randomized trial to compare completion and tolerability of 4 months Rifampin (4 RIF) and 9 months Isoniazid (9 INH) for treatment of latent TB in children

Click here to have more details on the protocolÌý

Click here to have access to the RCT 4v9 children publication

Click here to have access to the RCT 4v9 adult publicationÌýÌý


Ìý

Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Click here to read the study protocol

Meta-analysis of Individual patient Data (IPD) of Patients with Multi-Drug Resistant Tuberculosis. Click here for resources related to this project.

Ìý

Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý

Ìý

Ìý

Ìý

Partnerships

PAHO/WHO Collaborating Centers

Ìý

Advancing New TB Vaccines for the World

Our vision:ÌýA world where diagnosis guides the way to health for all people

Our mission:ÌýTurning complex diagnostic challenges into simple solutions to overcome diseases of poverty and transform lives

Manipal Centre for Infectious Disease based at Manipal University,ÌýKarnataka, India

SGC is aÌýpublic-private partnership that supports the discovery of new medicines through open access research.Ìý

TB REACH: FINDING AND TREATING PEOPLE WITH TB IN THE WORLD’S POOREST COMMUNITIES

Ìý

Partnership involvement

TB Alliance is a not-for-profit organization dedicated to the discovery and development of better, faster-acting, and affordable tuberculosis drugs that are available to those who need them.


Ìý

Back to top